Shots:
The US FDA has approved Dupixent to treat CSU pts (≥12yrs.), who were symptomatic despite H1 antihistamine treatment based on 2 P-III (Study A & C) trials from LIBERTY-CUPID program; regulatory review ongoing in EU & other regions
Study A & C assessed Dupixent (loading dose then 300mg Q2W; pts weighing <60kg received 200mg)…
